FDA OKs Octreotide Capsules; COVID-19 Damages Endocrine System

(MedPage Today) — The FDA approved octreotide (Mycapssa) capsules for long-term maintenance of acromegaly in those already treated with octreotide or lanreotide, Chiasma announced.
Certain medication and medical devices may inadvertently expose…

Source link

Related posts

Here’s Food for Thought—and School Success


Effective Discipline to Raise Healthy Children


Which Commonly Prescribed Drug is More Effective for Infants with Epilepsy?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World